For those in the diabetes community who’ve dreamed about seeing their in-the-moment blood sugar readings and trend data right on their smartwatch or bike computer while exercising, Dexcom and Garmin ...
(COLORADO SPRINGS) — FOX21 News has learned alternative ways people are getting around the shortage of the medical device called the Dexcom, a glucose monitor for diabetes. Some diabetics are now ...
Elsewhere, the company's Casgevy, approved some two years ago to treat two rare blood disorders, could also make commercial ...
Zacks Investment Research on MSN
Here's why you should hold DexCom stock in your portfolio for now
DexCom, Inc. DXCM is well-poised for growth in the coming quarters, backed by a huge potential in the continuous glucose monitoring (CGM) market. A strong third-quarter 2025 performance and a series ...
TipRanks on MSN
DEXCOM call volume above normal and directionally bullish
Bullish option flow detected in DexCom (DXCM) with 1,753 calls trading, 1.1x expected, and implied vol increasing almost 2 points to 45.27%.
We think that DexCom stock (NASDAQ NDAQ: DXCM) is currently a better pick than Insulet stock (NASDAQ: PODD), given DexCom’s DXCM better prospects and comparatively lower valuation. DXCM stock trades ...
DexCom announced that Chairman and CEO Kevin R. Sayer has taken a temporary medical leave as of September 14, 2025, with President and COO Jacob S. Leach appointed interim CEO and Mark Foletta as ...
Oura and Dexcom are partnering on metabolic health — and they mean big business. Dexcom has invested $75 million into Oura to make the deal happen, valuing Oura at $5 billion. That works out to just a ...
Levi & Korsinsky, LLP notifies investors in DexCom, Inc. ("DexCom" or the "Company") (NASDAQ: DXCM) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on ...
More than a decade after coining “Treat Yo’ Self Day” in her role as Donna on “Parks & Recreation,” Retta is once again helping establish a new annual observance. Glucose sensor maker Dexcom and ...
DexCom, Inc.'s growth is impressive but limited by its niche market, with my projected ceiling being ~$7.5bn in peak annual revenues. Despite positive Q4 2024 results, DexCom's stock is fairly valued, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results